Paeoniflorin attenuates neuroinflammation and dopaminergic neurodegeneration in the MPTP model of Parkinson's disease by activation of adenosine A 1 receptor

British Journal of Pharmacology

Volumn 148, Issue 3, 2006, Pages 314-325

  Liu, Hua Qing ^a   Zhang, Wei Yu ^a   Luo, Xue Ting ^a   Ye, Yang ^a   Zhu, Xing Zu ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Adenosine A 1 receptor; Mice; MPTP; Neuroinflammation; Neuroprotection; Paeoniflorin; Parkinson's diease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; ADENOSINE A1 RECEPTOR; ADENOSINE A1 RECEPTOR ANTAGONIST; HERBACEOUS AGENT; PAEONIFLORIN; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BRADYKINESIA; BRAIN NERVE CELL; CELL ACTIVATION; CELL DEATH; CHINESE HERB; CONTROLLED STUDY; DISEASE MODEL; DOPAMINERGIC NERVE CELL; DRUG EFFECT; INFLAMMATION; MALE; MICROGLIA; MOUSE; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PAEONIA; PARKINSON DISEASE; PREMEDICATION; PRIORITY JOURNAL; SUBSTANTIA NIGRA; UPREGULATION;

ANIMALS; BENZOIC ACIDS; BRIDGED COMPOUNDS; CORPUS STRIATUM; DOPAMINE; GLUCOSIDES; INFLAMMATION; MICE; NERVE FIBERS; NEURONS; NEUROPROTECTIVE AGENTS; NEUROTOXICITY SYNDROMES; PARKINSONIAN DISORDERS; RECEPTOR, ADENOSINE A1; SUBSTANTIA NIGRA;

EID: 33744497031     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706732     Document Type: Article

References (77)

1. ALEXANDER, S.P. & REDDINGTON, M. (1989). The cellular localization of adenosine receptors in rat neostriatum. Neuroscience, 3, 645-651.
2. ALFINITO, P.D., WANG, S.P., MANZINO, L., RIJHSINGHANI, S., ZEEVALK, G.D. & SONSALLA, P.K. (2003). Adenosinergic protection of dopaminergic and GABAergic neurons against mitochondrial inhibition through receptors located in the substantia nigra and striatum, respectively. J. Neurosci., 23, 10982-10987.
3. ARAKI, T., MIZUTANI, H., MATSUBARA, M., IMAI, Y., MIZUGAKI, M. & ITOYAMA, Y. (2001). Nitric oxide synthase inhibitors cause motor deficits in mice. Eur. Neuropsycho. Pharmacol., 11, 125-133.
4. BENNER, E.J., MOSLEY, R.L., DESTACHE, C.J., LEWIS, T.B., JACKSON-LEWIS, V., GORANTLA, S., NEMACHEK, C., GREEN, S.R., PRZEDBORSKI, S. & GENDELMAN, H.E. (2004). Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease. Proc. Natl. Acad. Sci. U.S.A., 101, 9435-9440.
5. BOUMA, M.G., STAD, R.K., VAN DEN WILDENBERG, F.A. & BUURMAN, W.A. (1994). Differential regulatory effects of adenosine on cytokine release by activated human monocytes. J. Immunol., 153, 4159-4168.
6. BOYLE, D.L., SAJJADI, F.G. & FIRESTEIN, G.S. (1996). Inhibition of synoviocyte collagenase gene expression by adenosine receptor stimulation. Arthritis. Rheum., 39, 923-930.
7. CHEN, J.F., XU, K., PETZER, J.P., STAAL, R., XU, Y.H., BEILSTEIN, M., SONSALLA, P.K., CASTAGNOLI, K., CASTAGNOLI Jr, N. & SCHWARZSCHILD, M.A. (2001). Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. J. Neurosci., 21, RC143.
8. CHENG, J.T., WANG, C.J. & HSU, F.L. (1999). Paeoniflorin reverses guanethidine-induced hypotension viaactivation of central adenosine A1 receptors in Wistar rats. Clin. Exp. Pharmacol. Physiol., 26, 815-816.
9. COGGESHALL, R.E. (1992). A consideration of neural counting methods. Trends Neurosci., 15, 9-13.
10. COLLIS, M.G. & HOURANI, S.M. (1993). Adenosine receptor subtypes. Trends Pharmacol. Sci., 14, 360-366.
11. CONTI, B., SUGAMA, S., LUCERO, J., WINSKY-SOMMERER, R., WIRZ, S.A., MAHER, P., ANDREWS, Z., BARR, A.M., MORALE, M.C., PANEDA, C., PEMBERTON, J., GAIDAROVA, S., BEAL, F., SANNA, P.P., HORVATH, T. & BARTFAI, T. (2005). Uncoupling protein 2 protects dopaminergic neurons from acute 1,2,3,6-methylphenyl-tetrahydropyridine toxicity. J. Neurochem., 93, 493-501.
12. CROCKER, S.J., SMITH, P.D., JACKSON-LEWIS, V., LAMBA, W.R., HAYLEY, S.P., GRIMM, E., CALLAGHAN, S.M., SLACK, R.S., MELLONI, E., PRZEDBORSKI, S., ROBERTSON, G.S., ANISMAN, H., MERALI, Z. & PARK, D.S. (2003). Inhibition of calpains prevents neuronal and behavioral deficits in an MPTP mouse model of Parkinson's disease. J. Neurosci., 23, 4081-4091.
13. CRONSTEIN, B.N. (1994). Adenosine, an endogenous anti-inflammatory agent. J. Appl. Physiol., 76, 5-13.
14. DAVAL, J.L., NEHLIG, A. & NICOLAS, F. (1991). Physiological and pharmacological properties of adenosine: therapeutic implications. Life Sci., 49, 1435-1453.
15. DEGIORGIO, L.A., DIBINIS, C., MILNER, T.A., SAJI, M. & VOLPE, B.T. (1998). Histological and temporal characteristics of nigral transneuronal degeneration after striatal injury. Brain Res., 795, 1-9.
16. DELLEDONNE, K.T. & SONSALLA, P.K. (1994). Protection against methamphetamine-induced neurotoxicity to neostriatal dopaminergic neurons by adenosine receptor activation. J. Pharmacol. Exp. Ther., 271, 1320-1326.
17. DE MENDONÇA, A., SEBASTIÃO, A.M. & RIBEIRO, J.A. (2000). Adenosine: does it have a neuroprotective role after all? Brain Res. Rev., 33, 258-274.
18. DEZAKI, K., KIMURA, I., MIYAHARA, K. & KIMURA, M. (1996). Complementary effects of paeoniflorin and glycyrrhizin on intracellular Ca2+ mobilization in the nerve-stimulated skeletal muscle of mice. Jap. J. Pharmacol., 69, 281-284.
19. FERGER, B., LENG, A., MURA, A., HENGERER, B. & FELDON, J. (2004). Genetic ablation of tumor necrosis factor-alpha (TNF-alpha) and pharmacological inhibition of TNF-synthesis attenuates MPTP toxicity in mouse striatum. J. Neurochem., 89, 822-833.
20. FRANCIS, J.W., VON VISGER, I., MARKELONIS, G.J. & OH, T.H. (1995). Neuroglial responses to the dopaminergic neurotoxicant 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine in mouse striatum. Neurotoxicol. Teratol., 17, 7-12.
21. FURUYA, T., HAYAKAWA, H., YAMADA, M., YOSHIMI, K., HISAHARA, S., MIURA, M., MIZUNO, Y. & MOCHIZUKI, H. (2004). Caspase-11 mediates inflammatory dopaminergic cell death in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. J. Neurosci., 24, 1865-1872.
22. GAO, H.M., LIU, B., ZHANG, W. & HONG, J.S. (2003). Novel antiinflammatory therapy for Parkinson's disease. Trends. Pharmacol. Sci., 24, 395-401.
23. 2A adenosine receptors attenuate methamphetamine-induced overflow of dopamine in rat striatum. Brain Res., 806, 202-209.
24. GRUNBLATT, E., MANDEL, S. & YOUDIM, M.B. (2000). MPTP and 6-hydroxydopamine-induced neurodegeneration as models for Parkinson's disease: neuroprotective strategies. J. Neurol., 247 (Suppl 2), II95-II102.
25. GUNDERSEN, H.J. (1992). Stereology: the fast lane between neuroanatomy and brain function - or still only a tightrope? Acta. Neurol. Scand., 137 (Suppl), 8-13.
26. HASKO, G., SZABO, C., NEMETH, Z.H., KVETAN, V., PASTORES, S.M. & VIZI, E.S. (1996). Adenosine receptor agonists differentially regulate IL-10, TNF-alpha, and nitric oxide production in RAW 264.7 macrophages and in endotoxemic mice. J. Immunol., 157, 4634-4640.
27. HEBERT, G., MINGAM, R., ARSAUT, J., DANTZER, R. & DEMOTES-MAINARD, J. (2005). A role of IL-1 in MPTP-induced changes in striatal dopaminergic and serotoninergic transporter binding: clues from interleukin-1 type I receptor-deficient mice. Brain Res. Mol. Brain. Res., 136, 267-270.
28. HSU, F.L., LAI, C.W. & CHENG, J.T. (1997). Antihyperglycemic effects of paeoniflorin and 8-debenzoylpaeoniflorin, glucosides from the root of Paeonia lactiflora. Planta Medica., 63, 323-325.
29. HUNOT, S. & HIRSCH, E.C. (2003). Neuroinflammatory processes in Parkinson's disease. Ann. Neurol., 53, S49-S60.
30. IWASHITA, A., YAMAZAKI, S., MIHARA, K., HATTORI, K., YAMAMOTO, H., ISHIDA, J., MATSUOKA, N. & MUTOH, S. (2004). Neuroprotective effects of a novel poly(ADP-ribose) polymerase-1 inhibitor, 2-[3-[4-(4-chlorophenyl)-1- piperazinyl] propyl]-4(3H)-quinazolinone (FR255595), in an in vitro model of cell death and in mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J. Pharmacol. Exp. Ther., 309, 1067-1078.
31. 1 receptor expression on macrophages in brain and blood of patients with multiple sclerosis. Ann. Neurol., 49, 650-658.
32. KATO, H., KUROSAKI, R., OKI, C. & ARAKI, T. (2004). Arundic acid, an astrocyte-modulating agent, protects dopaminergic neurons against MPTP neurotoxicity in mice. Brain Res., 1030, 66-73.
33. KAY, J.N. & BLUM, M. (2000). Differential response of ventral midbrain and striatal progenitor cells to lesions of the nigrostriatal dopaminergic projection. Dev. Neurosci., 22, 56-67.
34. KIM, W.G., MOHNEY, R.P., WILSON, B., JEOHN, G.H., LIU, B. & HONG, J.S. (2000). Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia. J. Neurosci., 20, 6309-6316.
35. KOHUTNICKA, M., LEWANDOWSKA, E., KURKOWSKA-JASTRZEBSKA, I., CZLONKOWSKI, A. & CZLONKOWSKA, A. (1998). Microglial and astrocytic involvement in a murine model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP). Immunopharmacology, 39, 167-180.
36. KREUTZBERG, G.W. (1996). Microglia: a sensor for pathological events in the CNS. Trends Neurosci., 19, 312-318.
37. KURKOWSKA-JASTRZEBSKA, I., WRONSKA, A., KOHUTNICKA, M., CZLONKOWSKI, A. & CZLONKOWSKA, A. (1999). The inflammatory reaction following 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine intoxication in mouse. Exp. Neurol., 156, 50-61.
38. KUROSAKI, R., MURAMATSU, Y., KATO, H. & ARAKI, T. (2004). Biochemical, behavioral and immunohistochemical alterations in MPTP-treated mouse model of Parkinson's disease. Pharmacol. Biochem. Behav., 78, 143-153.
39. LAI, C.W., HSU, F.L. & CHENG, J.T. (1998). Stimulatory effect of paeoniflorin on adenosine A1 receptors to increase the translocation of protein kinase C (PKC) and glucose transporter (GLUT 4) in isolated rat white adipocytes. Life Sci., 62, 1591-1595.
40. LAU, Y.S. & MOURADIAN, M.M. (1993). Protection against acute MPTP-induced dopamine depletion in mice by adenosine A1 agonist. J. Neurochem., 60, 768-771.
41. LAWSON, L.J., PERRY, V.H., DRI, P. & GORDON, S. (1996). Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience, 39, 151-170.
42. LE MOINE, O., STORDEUR, P., SCHANDENE, L., MARCHANT, A., DE GROOTE, D., GOLDMAN, M. & DEVIERE, J. (1996). Adenosine enhances IL-10 secretion by human monocytes. J. Immunol., 156, 4408-4414.
43. LIBERATORE, G.T., JACKSON-LEWIS, V., VUKOSAVIC, S., MANDIR, A.S., VILA, M., MCAULIFFE, W.G., DAWSON, V.L., DAWSON, T.M. & PRZEDBORSKI, S. (1999). Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat. Med., 5, 1403-1409.
44. LIU, B. & HONG, J.S. (2003). Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. J. Pharmacol. Exp. Ther., 304, 1-7.
45. 1 receptor in a different manner from its classical agonists. Br. J. Pharmacol., 146, 604-611.
46. MARCHETTI, B., SERRA, P.A., TIROLO, C., L'EPISCOPO, F., CANIGLIA, S., GENNUSO, F., TESTA, N., MIELE, E., DESOLE, S., BARDEN, N. & MORALE, M.C. (2005). Glucocorticoid receptor-nitric oxide crosstalk and vulnerability to experimental parkinsonism: pivotal role for glia-neuron interactions. Brain Res. Brain Res Rev., 48, 302-321.
47. MATSUURA, K., KABUTO, H., MAKINO, H. & OGAWA, N. (1997). Pole test is a useful method for evaluating the mouse movement disorder caused by striatal dopamine depletion. J. Neurosci. Methods, 73, 45-48.
48. MCGEER, P.L., ITAGAKI, S., BOYES, B.E. & MCGEER, E.G. (1988). Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology, 38, 1285-1291.
49. MERRILL, J.E. & BENVENISTE, E.N. (1996). Cytokines in inflammatory brain lesions: helpful and harmful. Trends Neurosci., 19, 331-338.
50. MOGI, M., HARADA, M., KONDO, T., RIEDERER, P., INAGAKI, H., MINAMI, M. & NAGATSU, T. (1994a). Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci. Lett., 180, 147-150.
51. MOGI, M., HARADA, M., RIEDERER, P., NARABAYASHI, H., FUJITA, K. & NAGATSU, T. (1994b). Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci. Lett., 165, 208-210.
52. MOGI, M., TOGARI, A., OGAWA, M., IKEGUCHI, K., SHIZUMA, N., FAN, D., NAKANO, I. & NAGATSU, T. (1998). Effects of repeated systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to mice on interleukin- 1beta and nerve growth factor in the striatum. Neurosci. Lett., 250, 25-28.
53. OLAH, M.E. & STILES, G.L. (1995). Adenosine receptor subtypes: characterization and therapeutic regulation. Annu. Rev. Pharmacol. Toxicol., 35, 581-586.
54. ONGINI, E. & SCHUBERT, P. (1998). Neuroprotection induced by stimulating A1 or blocking A2A adenosine receptors: an apparent paradox. Drug Dev. Res., 45, 387-393.
55. POWER, C., HENRY, S., DEL BIGIO, M.R., LARSEN, P.H., CORBETT, D., IMAI, Y., YONG, V.W. & PEELING, J. (2003). Intracerebral hemorrhage induces macrophage activation and matrix metalloproteinases. Ann Neurol., 53, 731-741.
56. PRZEDBORSKI, S. & JACKSON-LEWIS, V. (1998). Experimental developments in movement disorders: update on proposed free radical mechanisms. Curr. Opin. Neurol., 11, 35-339.
57. RUDOLPHI, K., SCHUBERT, P., PARKINSON, F.E. & FREDHOLM, B.B. (1992). Neuroprotective role of adenosine in cerebral ischaemia. Trends Pharmacol. Sci., 13, 439-445.
58. SAJJADI, F.G., TAKABAYASHI, K, FOSTER, A.C., DOMINGO, R.C. & FIRESTEIN, G.S. (1996). Inhibition of TNF-alpha expression by adenosine: role of A3 adenosine receptors. J. Immunol., 156, 3435-3442.
59. SCHNEIDER, J.S. & DENARO, F.J. (1988). Astrocytic responses to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in cat and mouse brain. J. Neuropathol. Exp. Neurol., 47, 452-458.
60. SCHWANINGER, M., NEHER, M., VIEGAS, E., SCHNEIDER, A. & SPRANGER, M. (1997). Stimulation of interleukin-6 secretion and gene transcription in primary astrocytes by adenosine. J. Neurochem., 69, 1145-1150.
61. SHEN, Y.Q., HEBERT, G., LIN, L.Y., LUO, Y.L., MOZE, E., LI, K.S. & NEVEU, P.J. (2005). Interleukine-1beta and interleukine-6 levels in striatum and other brain structures after MPTP treatment: influence of behavioral lateralization. J. Neuroimmunol., 158, 14-25.
62. SOLTYS, Z., ZIAJA, M., PAWLINSKI, R., SETKOWICZ, Z. & JANECZKO, K. (2001). Morphology of reactive microglia in the injured cerebral cortex. Fractal analysis and complementary quantitative methods. J. Neurosci. Res., 63, 90-97.
63. SUGAMA, S., YANG, L., CHO, B.P., DEGIORGIO, L.A., LORENZL, S., ALBERS, D.S., BEAL, M.F., VOLPE, B.T. & JOH, T.H. (2003). Age-related microglial activation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurodegeneration in C57BL/6 mice. Brain Res., 964, 288-294.
64. SUGISHITA, E., AMAGAYA, S. & OGIHARA, Y. (1984). Studies on the combination of Glycyrrhizae Radix in Shakuyakukanzo-To. J. Pharmacobiodyn., 7, 427-435.
65. TAKEDA, S., ISONO, T., WAKUI, Y., MATSUZAKI, Y., SASAKI, H., AMAGAYA, S. & MARUNO, M. (1995). Absorption and excretion of paeoniflorin in rats. J. Pharm. Pharmacol., 47, 1036-1040.
66. TAMAYA, T., SATO, S. & OKADA, H.H. (1986). Possible mechanism of steroid action of the plant herb extracts glycyrrhizin, glycyrrhetinic acid, and paeoniflorin: inhibition by plant herb extracts of steroid protein binding in the rabbit. Ameri. J. Obstetrics. Gynecol., 155, 1134-1139.
67. TANG, L.M., LIU, I.M. & CHENG, J.T. (2003). Stimulatory effect of paeoniflorin on adenosine release to increase the glucose uptake into white adipocytes of Wistar rat. Planta. Med., 69, 332-336.
68. TEISMANN, P., TIEU, K., CHOI, D.K., WU, D.C., NAINI, A., HUNOT, S., VILA, M., JACKSON-LEWIS, V. & PRZEDBORSKI, S. (2003). Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc. Natl. Acad. Sci. U.S.A., 100, 5473-5478.
69. TSUTSUI, S., SCHNERMANN, J., NOORBAKHSH, F., HENRY, S., YONG, V.W., WINSTON, B.W., WARREN, K. & POWER, C. (2004). A1 adenosine receptor up-regulation and activation attenuates neuroinflammation and demyelination in a model of multiple sclerosis. J. Neurosci., 24, 1521-1529.
70. VAN SCHAICK, E.A., MATH-OT, R.A., GUBBENS-STIBBE, J.M., LANGEMEIJER, M.W., ROELEN, H.C., IJZERMAN, A.P. & DANHOF, M. (1997). 8-Alkylamino- substituted analogs of N6-cyclopentyladenosine are partial agonists for the cardiovascular adenosine A1 receptors in vivo. J. Pharmacol. Exp. Ther., 283, 800-808.
71. VOLPE, B.T., WILDMANN, J. & ALTAR, C.A. (1998). Brain-derived neurotrophic factor prevents the loss of nigral neurons induced by excitotoxic striatal-pallidal lesions. Neuroscience, 83, 741-748.
72. VON LUBITZ, D.K.J.E. (1999). Adenosine and cerebral ischemia: therapeutic future or death of a brave concept. Eur. J. Pharmacol., 365, 9-25.
73. WU, D.C., JACKSON-LEWIS, V., VILA, M., TIEU, K., TEISMANN, P., VADSETH, C., CHOI, D.K., ISCHIROPOULOS, H. & PRZEDBORSKI, S. (2002). Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine mouse model of Parkinson disease. J. Neurosci., 22, 1763-1771.
74. YAMAHARA, J., YAMADA, T., KIMURA, H., SAWADA, T. & FUJIMURA, H. (1982). Biologically active principles of crude drugs. II. Anti-allergic principles in 'Shoseiryu-To' anti-inflammatory properties of paeoniflorin and its derivatives. J. Pharmacobiodyn., 5, 921-929.
75. YANG, J., HE, L.N., HE, S.B. & LI, G.R. (2001). Protective effect of paeoniflorin on calcium overloading injury in cultured primary cortex neurons. Chin. J. Pharmacol. Toxicol., 15, 164-168.
76. ZHOU, H.F., LIU, X.Y., NIU, D.B., LI, F.Q., HE, Q.H. & WANG, X.M. (2005). Triptolide protects dopaminergic neurons from inflammation-mediated damage induced by lipopolysaccharide intranigral injection. Neurobiol. Dis., 18, 441-449.
77. ZARRINDAST, M.R., NAGHIPOUR, B., ROUSHAN-ZAMIR, F. & SHAFAGHI, B. (1999). Effects of adenosine receptor agents on the expression of morphine withdrawal in mice. Eur. J. Pharmacol., 369, 17-22.